Analytical Data
-
基因名
Ba71V-107
- Application
-
别名
Ba71V-107；
-
种属
E.coli
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q89424
-
表达区间
1-117aa
-
氨基酸序列
MDTETSPLLSHNLSTREGIKQSTQGLLAHTIARYPGTTAILLGILILLVIILIIVAIVYYNRSVDCKSSMPKPPPSYYVQQPEPHHHFPVFFRKRKNSTSLQSHIPSDEQLAELAHS
-
分子量
13.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Ba71V-107, a recombinant protein derived from the Ba71V strain of the vesicular stomatitis virus (VSV), has garnered significant attention in the field of virology and vaccine development. The Ba71V strain exhibits unique pathogenicity and immunogenic properties, making it a valuable model for studying viral behavior and host interactions. Research on Ba71V-107 focuses on its potential as a vaccine candidate due to its ability to elicit robust immune responses. This protein's structure and function have been characterized to investigate how it interacts with the host immune system, providing insights into the development of innovative therapeutic strategies against VSV and similar viruses. Additionally, Ba71V-107 has been explored for its applicability in oncolytic virotherapy, wherein engineered viruses selectively target and destroy cancer cells while sparing normal tissues. The study of Ba71V-107 not only contributes to advancements in viral research but also holds promise for the development of effective vaccines and treatments against various diseases, highlighting the need for ongoing research in this area.
